Page last updated: 2024-09-03

gefitinib and pf-06463922

gefitinib has been researched along with pf-06463922 in 2 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(pf-06463922)
Trials
(pf-06463922)
Recent Studies (post-2010) (pf-06463922)
5,2315662,91922927224

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)pf-06463922 (IC50)
Sodium-dependent phosphate transport protein 2BHomo sapiens (human)0.0002
HLA class II histocompatibility antigen gamma chainHomo sapiens (human)0.0002
High affinity nerve growth factor receptorHomo sapiens (human)0.024
Tyrosine-protein kinase Fes/FpsHomo sapiens (human)0.006
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)0.0003
Tyrosine-protein kinase FerHomo sapiens (human)0.0033
Leukocyte tyrosine kinase receptorHomo sapiens (human)0.0027
Tyrosine-protein kinase FRKHomo sapiens (human)0.053
Focal adhesion kinase 1Homo sapiens (human)0.017
Activated CDC42 kinase 1Homo sapiens (human)0.017
Protein-tyrosine kinase 2-betaHomo sapiens (human)0.014
NT-3 growth factor receptorHomo sapiens (human)0.046
Echinoderm microtubule-associated protein-like 4Homo sapiens (human)0.0186
ALK tyrosine kinase receptorHomo sapiens (human)0.0177

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Ding, K; Lu, X; Smaill, JB1
Eisenstein, M1

Reviews

1 review(s) available for gefitinib and pf-06463922

ArticleYear
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
    Journal of medicinal chemistry, 2020, 10-08, Volume: 63, Issue:19

    Topics: Chemistry, Pharmaceutical; Humans; Point Mutation; Protein Kinase Inhibitors

2020

Other Studies

1 other study(ies) available for gefitinib and pf-06463922

ArticleYear
New lung-cancer drugs extend survival times.
    Nature, 2020, Volume: 587, Issue:7834

    Topics: Acrylamides; Afatinib; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Hope; Humans; Lactams; Lung; Lung Neoplasms; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Quinazolinones; Survival Analysis

2020